Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4647117
Max Phase: Preclinical
Molecular Formula: C26H34Cl2N6O2S
Molecular Weight: 565.57
Molecule Type: Unknown
Associated Items:
ID: ALA4647117
Max Phase: Preclinical
Molecular Formula: C26H34Cl2N6O2S
Molecular Weight: 565.57
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1nn([C@H](C)c2ccc(Cl)cc2Cl)c2nc(N3CC([C@H]4CCCN(CCCS(C)(=O)=O)C4)C3)cnc12
Standard InChI: InChI=1S/C26H34Cl2N6O2S/c1-17-25-26(34(31-17)18(2)22-8-7-21(27)12-23(22)28)30-24(13-29-25)33-15-20(16-33)19-6-4-9-32(14-19)10-5-11-37(3,35)36/h7-8,12-13,18-20H,4-6,9-11,14-16H2,1-3H3/t18-,19+/m1/s1
Standard InChI Key: DXXLKXHWTDGCBH-MOPGFXCFSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 565.57 | Molecular Weight (Monoisotopic): 564.1841 | AlogP: 4.63 | #Rotatable Bonds: 8 |
Polar Surface Area: 84.22 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 0 |
#RO5 Violations: 1 | HBA (Lipinski): 8 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: 7.96 | CX LogP: 3.08 | CX LogD: 2.41 |
Aromatic Rings: 3 | Heavy Atoms: 37 | QED Weighted: 0.39 | Np Likeness Score: -1.28 |
1. Robles O, Jackson JJ, Marshall L, Talay O, Chian D, Cutler G, Diokno R, Hu DX, Jacobson S, Karbarz E, Kassner PD, Ketcham JM, McKinnell J, Meleza C, Reilly MK, Riegler E, Shunatona HP, Wadsworth A, Younai A, Brockstedt DG, Wustrow DJ, Zibinsky M.. (2020) Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as a Single Agent and in Combination with Checkpoint Inhibitors., 63 (15): [PMID:32667798] [10.1021/acs.jmedchem.0c00988] |
Source(1):